Can Hypofractionated Reirradiation Plus Temozolamide Be a Wise Choice for Recurrent High and Low Grade Brain Tumors?

Abstract

Aim: To report outcome, toxicity, and survival of reirradition with hypofractionated radiotherapy concurrently temozolamide which is a novel approach to recurrent high-and lowgrade glioma patients. Material and Methods: Twenty patients (8 males and 12 females; age between 26 and 70 years) with reccurent gliomas treated in our clinic were included in our study. The primary pathology was low grade in 12 patients and high grade in 8 patients. For recurrence hypofractionated radiotherapy, 350 cGy/fraction, totally 3500 cGy with concomitant temozolamide 75 mg/m2/ day was applied. Results: Median OS was 55.42 months, median progression free survival was 38.26 months, and median survival from reirradiation was 9.3 months. Neither gender nor primary pathology had got effect on any of the survivals. Although being reoperated for recurrence did not affect progression free survival or survival after reirradiation, it has got statistically significant impact on overall survival. No severe toxicity was seen other than minor side effects. No interruption was needed so all of the patients were able to complete the treatment according to the scheduled plan. Conclusion: Reirradiation as hypofractionated radiotherapy with concomittant temozolamide is an effective, safe, and well-tolerated treatment for recurrent high and low glial tumors.